Sell on Novo Nordisk A/S: slowing growth, downgraded 2025 guidance, rising GLP-1 competition, pricing/patent risks, limited ...
Some products launched with hype, money, and confidence '€” only to crash spectacularly. Join us as we count down the most notorious product failures in history! From exploding phones to see-through ...